系统综述与荟萃分析:抗肿瘤坏死因子-α药物英夫利西单抗生物类似药CT-P13在炎症性肠病中的疗效与安全性
该系统综述与荟萃分析检索电子数据库,纳入11项观察性研究、829例使用英夫利西单抗生物类似药CT-P13的炎症性肠病患者,评估诱导治疗或转换治疗后的临床应答、缓解及不良事件合并率。结果显示CT-P13在克罗恩病和溃疡性结肠炎中均有良好疗效和安全性,支持其用于炎症性肠病治疗。
要点
- CT-P13诱导治疗8-14周临床应答合并率:克罗恩病0.79,溃疡性结肠炎0.74。
- 转换至CT-P13后持续临床应答合并率在30-32周为克罗恩病0.85、溃疡性结肠炎0.96。
- 不良事件罕见,诱导治疗阶段克罗恩病和溃疡性结肠炎合并率均为0.08。
核心结论
- CT-P13具有优良的临床疗效和安全性,支持其用于炎症性肠病的治疗。
研究设计与样本
- 系统综述与荟萃分析,检索电子数据库,纳入11项观察性研究,共829例使用英夫利西单抗生物类似药CT-P13的炎症性肠病患者。
主要发现
- 克罗恩病8-14周临床应答合并率为0.79(95%CI=0.65-0.88),溃疡性结肠炎为0.74(95%CI=0.65-0.82)。
- 克罗恩病24-30周临床应答合并率为0.77(95%CI=0.63-0.86),溃疡性结肠炎为0.77(95%CI=0.67-0.85)。
- 诱导治疗阶段不良事件合并率:克罗恩病0.08(95%CI=0.02-0.26),溃疡性结肠炎0.08(95%CI=0.03-0.17)。
- 从英夫利西单抗转换至CT-P13后30-32周持续临床应答合并率:克罗恩病0.85(95%CI=0.71-0.93),溃疡性结肠炎0.96(95%CI=0.58-1.00)。
- 转换后48-63周持续临床应答合并率:克罗恩病0.75(95%CI=0.44-0.92),溃疡性结肠炎0.83(95%CI=0.19-0.99)。
关键数值与推荐
- 克罗恩病转换后不良事件合并率为0.10(95%CI=0.02-0.31),溃疡性结肠炎为0.22(95%CI=0.04-0.63)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biosimilars of anti-tumour necrosis factor (TNF)-α agents have now become clinically available for the treatment of inflammatory bowel diseases (IBD). AIM: To perform a systematic review and meta-analysis to evaluate the efficacy and safety of biosimilars of anti-TNF-α agents in patients with IBD. METHODS: Electronic databases were searched. The outcomes were the pooled rates of clinical response or remission, sustained clinical response or remission, and adverse events in patients with IBD induced with or switched to biosimilars of anti-TNF-α agents. RESULTS: Eleven observational studies reporting outcomes in 829 patients treated with biosimilar of infliximab (CT-P13) were identified. The pooled rates of clinical response among Crohn's disease (CD) and ulcerative colitis (UC) at 8-14 weeks were 0.79 (95% confidence interval (CI) = 0.65-0.88) and 0.74 (95% CI = 0.65-0.82), respectively, and at 24-30 weeks were 0.77 (95% CI = 0.63-0.86) and 0.77 (95% CI = 0.67-0.85) respectively. Adverse events were rare (CD, 0.08 (95% CI = 0.02-0.26); UC, 0.08 (95% CI = 0.03-0.17)). The pooled rates of sustained clinical response among CD and UC after switching from infliximab to CT-P13 at 30-32 weeks were 0.85 (95% CI = 0.71-0.93) and 0.96 (95% CI = 0.58-1.00), respectively, and at 48-63 weeks were 0.75 (95% CI = 0.44-0.92) and 0.83 (95% CI = 0.19-0.99) respectively. Adverse events were rare (CD, 0.10, 95% CI = 0.02-0.31; UC, 0.22, 95% CI = 0.04-0.63). CONCLUSIONS: CT-P13 was associated with excellent clinical efficacy and safety profile, supporting its use in the treatment of IBD.
引用
- Komaki Y, Yamada A, Komaki F, et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017. PMID: 28239873. doi:10.1111/apt.13990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。